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Abstract 21 
The insulin-releasing effects, cellular mechanisms of action and anti-hyperglycaemic activity 22 
of 10 analogues of esculentin-2CHa lacking the cyclic C-terminal domain (CKISKQC) were 23 
evaluated. Analogues of the truncated peptide, esculentin-2CHa(1-30), were designed for 24 
plasma enzyme resistance and increased biological activity. Effects on insulin release, cell 25 
membrane integrity, membrane potential, intracellular Ca2+ and cAMP levels were 26 
determined using clonal BRIN-BD11 cells. Acute effects on glucose tolerance were 27 
investigated using NIH Swiss mice. D-amino acid substitutions at positions 7(Arg), 15(Lys) 28 
and 23(Lys) and fatty acid (L-octanoate) attachment to Lys at position 15 of esculentin-29 
2CHa(1-30) conveyed resistance to plasma enzyme degradation whilst preserving insulin-30 
releasing activity. Analogues [D-Arg7, D-Lys15, D-Lys23]-esculentin-2CHa(1-30)  and Lys15-31 
octanoate-esculentin-2CHa(1-30) exhibiting most promising profiles and with confirmed 32 
effects on both human insulin-secreting cells and primary mouse islets were selected for 33 
further analysis. Using chemical inhibition of adenylate cyclase, protein kinase C or 34 
phospholipase C pathways, involvement of PLC/PKC mediated insulin secretion was 35 
confirmed similar to that of CCK-8. Diazoxide, verapamil and Ca2+ omission inhibited 36 
insulin secretion induced by the esculentin-2CHa(1-30) analogues suggesting an action also 37 
on KATP and Ca2+ channels. Consistent with this, the analogues depolarised the plasma 38 
membrane and increased intracellular Ca2+. Evaluation with fluorescently labelled esculentin-39 
2CHa(1-30) indicated membrane action, with internalisation, but patch clamp experiments 40 
suggested that depolarisation was not due to direct inhibition of KATP channels. Acute 41 
administration of either analogue to NIH Swiss mice improved glucose tolerance and 42 
enhanced insulin release similar to that observed with GLP-1. These data suggest that multi-43 
acting analogues of esculentin-2CHa(1-30) may prove useful for glycaemic control in 44 
obesity-diabetes. 45 
 3 
 
Introduction 46 
Incidence of type 2 diabetes is constantly on the rise, owing to an increase in consumption of 47 
a western diet, sedentary lifestyle, obesity and aging population (Stumvoll et al. 2008, 48 
McCarthy, 2010). Current therapies targeting beta-cell secretory function and/or insulin 49 
action offer metabolic benefits but due to inability to restore normal  glycaemic control,  50 
diabetes associated complications arise including cardiovascular disease, neuropathy, 51 
nephropathy and retinopathy (McCarthy, 2010, Parkes et al. 2013, Kahn et al. 2014). As a 52 
result, there is a constant need for development of new, improved therapeutic agents to 53 
complement or replace existing anti-diabetic drugs.  Peptide hormone therapeutics and 54 
various glucagon-like peptide-1 (GLP-1 mimetics), have been strongly promoted over the 55 
past few years (Kahn et al. 2014, Irwin & Flatt, 2015). This approach has several potential 56 
advantages over development of small molecule drugs, providing greater specificity and 57 
improved safety (Parkes et al. 2013).  58 
In the 1980s, the search for bioactive agents in venoms of insects and reptiles led to 59 
the isolation and characterisation of exendin-4 from the salivary secretions of Heloderma 60 
suspectum (Gila monster) (Conlon et al. 2006). This peptide has been shown to stimulate 61 
insulin secretion and exert a range of glucoregulatory actions in a fashion similar to incretin 62 
hormone, GLP-1 (Parkes et al. 2013). Subsequently, long acting GLP-1 mimetics with good 63 
clinical efficacy and acceptable benefit-risk profiles have been developed for treatment of 64 
patients with type 2 diabetes (Irwin & Flatt, 2015). The search for naturally occurring 65 
bioactive agents has continued to date. Skin secretions of frogs and toads are a potentially 66 
valuable source of peptides that hold great therapeutic potential. Such molecules synthesized 67 
in the skin of amphibians (particularly the Hylidae (Nicolas & El Amri, 2009, Jackway et al. 68 
2011), Pipidae (Mechkarska et al. 2010), and Ranidae (Conlon, 2008, Conlon, 2011) 69 
families) are well known for their antimicrobial, antiviral, anti-tumor, immunomodulatory 70 
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and chemoattractive properties (Conlon et al. 2014). In addition, we have demonstrated that 71 
some of these host defence peptides isolated from frog skin secretions were insulinotropic in 72 
vitro and could improve glucose tolerance in animal models  in vivo (Conlon et al. 2014).  73 
Esculentin-2CHa (GFSSIFRGVAKFASKGLGKDLAKLGVDLVACKISKQC), 74 
isolated from norepinephrine-stimulated skin secretions of the Chiricahua leopard frog, 75 
Lithobates chiricahuensis (Ranidae), has been shown to exhibit  potent antimicrobial activity 76 
against clinical isolates of multidrug-resistant strains of Staphylococcus aureus, 77 
Acinetobacter baumannii, and Stenotrophomonas maltophilia (Conlon et al. 2011). In 78 
addition, this bioactive peptide also stimulated interleukin-10 (IL-10) release by mouse 79 
lymphoid cells and exerted cytotoxicity against human non-small lung adenocarcinoma A549 80 
cells with low haemolytic activity against human erythrocytes (Attoub et al. 2013). 81 
Increasing the cationicity of the peptide with L-Lysine substitution of Asp20 and Asp27 82 
residues enhanced antimicrobial activity while removal of either the hydrophobic N-terminal 83 
hexapeptide (GFSSIF) or the cyclic C-terminal domain (CKISKQC) and serine substitution 84 
of Cys31 and Cys37 residues decreased antimicrobial potency (Attoub et al. 2013). 85 
We recently reported anti-diabetic effects of an analogue of esculentin-2CHa – 86 
[Lys28]-esculentin-2CHa in high fat fed diabetic mice (Ojo et al. 2015c). Our previous 87 
observations indicate that any modification of frog skin peptides resulting in loss or reduction 88 
of antimicrobial activity also resulted in compromise of insulinotropic action. Interestingly, 89 
our preliminary observations revealed that loss of antimicrobial activity associated with 90 
removal of the cyclic C-terminal domain of esculentin-2CHa was not accompanied by 91 
abolition of insulinotropic actions in vitro. In other words, the truncated form of esculentin-92 
2CHa with 30 amino acid residues (esculentin-2CHa-GA30) and lacking the C-terminal 93 
disulphide bond stimulated insulin release from BRIN-BD11 cells.  94 
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Based on this and with a view to generating more easily synthesised/cost effective 95 
forms of esculentin-2CHa with potential as a possible new class of therapeutic peptides for 96 
diabetes, we designed a family of 10 analogues of esculentin-2CHa(1-30) as indicated in 97 
Table 1.  D-isomers of naturally occurring amino acids were substituted at positions 7, 15 and 98 
23 (Peptides 2-6) to confer resistance to endopeptidases based on the observed degradation 99 
pattern of the peptide in plasma. In addition, lysine residues at positions 15 and 23 were 100 
substituted with L-ornithine with a view to increasing metabolic stability (Peptide 7) and 101 
amidation of C-terminus (Peptide 8). To prolong half-life in the circulation (by facilitating 102 
binding to serum albumin), analogues were synthesised with a C-8 fatty acid (octanoate) 103 
attached to the lysine residue at position 15 or 23 (Peptides 9 or 10. Using the parent 104 
esculentin-2CHa(1-30) (Peptide 1) as positive control, we investigated these various modified 105 
analogues for enzymatic stability, insulinotropic effects, cellular mechanisms of action and 106 
acute antihyperglycaemic effects in vivo. 107 
Materials and methods 108 
Peptide synthesis and purification: Synthetic esculentin-2CHa(1-30) and analogues (Table 109 
1) were purchased (> 95 % pure) from GL Biochem Ltd (Shanghai, China) and purified to 110 
near homogeneity (> 98 % pure) by reversed-phase HLPC on a (2.2 cm x 25 cm) Vydac 111 
218TP1022 (C18) column equilibrated with acetonitrile/water/triflouroacetic acid (TFA) 112 
(21.0/78.9/0.1 v/v) mobile phase at a flow rate of 1 ml/min. The concentration of acetonitrile 113 
in the eluting buffer was raised to 56% (v/v) over 60 min. The molecular masses of the 114 
peptides were confirmed using MALDI-TOF mass spectrometry (Table 1). Other peptides 115 
including the enzyme resistant form of CCK-8, pggCCK-8 (Irwin et al. 2013) were purchased 116 
from American Peptide Company (Sunnyvale, CA, USA). 117 
Peptide degradation studies: Susceptibility of esculentin-2CHa(1-30) and related peptides to 118 
plasma proteolytic enzymes was determined by incubating the peptides with plasma (10 μl) 119 
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from fasted NIH Swiss mice in 50 mM triethanolamine-HCl buffer (pH 7.8) at 37 °C 120 
(O’Harte et al. 2001) for 0/8 h. The reactions were stopped by adding 10% (v/v) TFA/water 121 
(10 μl). Separation of intact and degraded products was carried out using reversed phase 122 
HPLC with a Vydac C-18 column equilibrated with 0.12% (v/v) TFA/water at a flow rate of 123 
1.0 ml/min. The concentration of acetonitrile in the eluting solution was increased over a 124 
linear gradient from 0 to 28% in 10 min, to 56% in 20 min and from 56% to 70% in 5 min. 125 
MALDI-TOF mass spectrometry was used to ascertain the molecular masses of both intact 126 
and degraded products. 127 
Cell culture: Insulin-secreting BRIN-BD11 rat clonal beta cells and 1.1B4 human clonal beta 128 
cells were routinely cultured in RPMI-1640 medium supplemented with 10 % (v/v) FBS and 129 
1 % (v/v) antibiotics – penicillin (100 U/ml) and streptomycin (0.1 mg/ml). The generation, 130 
culture and characteristics of these two cell lines have been described previously 131 
(McClenaghan et al. 1996, McCluskey et al. 2011) 132 
In vitro insulin-releasing studies: In vitro insulin-releasing effects of esculentin-2CHa(1-30) 133 
and its analogues were assessed using clonal beta cell lines as well as isolated mouse 134 
pancreatic islets. Firstly, BRIN-BD11 cells were incubated with the peptides in the 135 
concentration range (1 x 10-12 – 3 x 10-6M) in Krebs-Ringer bicarbonate buffer (KRBB) 136 
containing 5.6mM glucose for 20 min at 37 °C as previously described (Abdel-Wahab et al. 137 
2008, Mechkarska et al. 2011, Ojo et al. 2011). Effects of established modulators of insulin 138 
release, removal of extracellular  Ca2+ and  inhibitors of  phospholipase C (U73122) and 139 
adenylate cyclase (NKY80) were also tested  (Abdel-Wahab et al. 2008, Mechkarska et al. 140 
2011, Ojo et al. 2011). Plasma membrane integrity was assessed by measuring lactate 141 
dehydrogenase (LDH) in cell incubation buffer using CytoTox 96 non-radioactive 142 
cytotoxicity assay kit (Promega, Madison, WI, USA) according to the manufacturer’s 143 
instructions. In a second set of experiments, insulin releasing effects of esculentin-2CHa(1-144 
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30) and selected analogues were examined over a similar concentration range using 1.1B4 145 
human clonal beta cells (McCluskey et al. 2011, Green et al. 2015). In a third set of 146 
experiments, pancreatic islets isolated from NIH Swiss mice by collagenase digestion (Gotoh 147 
et al. 1985), were incubated with 10-6 and 10-8M  of esculentin-2CHa(1-30) and selected 148 
analogues for 1 h in Krebs-Ringer bicarbonate (KRB) buffer supplemented with 3 or 20 mM 149 
glucose. Other experiments detailed below were conducted at peptide concentration of 10-6M 150 
which elicited prominent insulin secretory effects. Insulin release was measured by 151 
radioimmunoassay (Flatt & Bailey, 1981a, Flatt & Bailey, 1981b) using mouse or human 152 
insulin standards as appropriate.  153 
Membrane potential studies and intracellular calcium ([Ca2+]i): Effects of esculentin-154 
2CHa(1-30) and analogues on membrane potential and intracellular calcium [Ca2+]i were 155 
assessed using BRIN-BD11 cells  (FLIPR membrane or calcium assay kit, Molecular 156 
Devices, USA) as previously described (Miguel et al. 2004). BRIN-BD11 cells were 157 
incubated with Krebs-Ringer bicarbonate buffer containing 5.6mM glucose.  Esculentin-158 
2CHa(1-30) and its analogues were added, with calcium mobilisation data collected and 159 
analysed using Softmax Pro software (Miguel et al. 2004). 160 
Membrane binding and patch-clamp electrophysiology 161 
For membrane binding studies, BRIN–BD11 cells were seeded onto polysine coated slides 162 
(40,000 cells/slide) and cultured overnight. Media was replaced with KRBB containing 1 µM 163 
FITC-esculentin-2CHa(1-30) and incubated for 5-90 minutes. Coverslips were washed with 164 
PBS, rapidly transferred to the recording bath (containing fresh PBS) mounted on an inverted 165 
microscope (Leica DMI6500B) coupled to a Leica TCS SP5 II confocal. Cells were excited 166 
by an argon laser (488nm) and simultaneously viewed on the transmitted light channel to 167 
allow assessment of the distribution of FITC-esculentin-2CHa(1-30) on plasma membrane 168 
and cytosolic compartments of the cells. Ionic currents were recorded from BRIN-BD11 169 
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pancreatic β-cells using the whole-cell mode of the patch clamp technique as previously 170 
described (Ojo et al. 2016). Amphotericin B was included in the pipette solutions to perforate 171 
the membrane and reduce current run-down such that currents were stable for the duration of 172 
the recording (Ojo et al. 2016). Current densities were calculated by dividing current 173 
amplitudes by the whole-cell capacitance (6-19 pF). External drug containing solutions were 174 
applied using a gravity-driven perfusion system with an exchange time of approximately 1s 175 
(Scholfield & Curtis, 2000). KATP currents were elicited by ramp protocols from +20 to -80 176 
mV applied over 1 second from a holding potential of 0 mV using high K+ external solution 177 
(containing in mM: 130 KCl, 10 TEACl, 2.5 Glucose, 1.3 MgCl2, 2 CaCl2, 10 HEPES pH 7.4 178 
with NaOH). 100nM penitrem A, 1mM 4,4′-diisothiocyanatostilbene-2,2′-disulfonate (DIDS) 179 
and 1μM nimodipine were added to inhibit BK, Cl-  and L-Type Ca2+ channels and a K+-180 
based internal (pipette) solution was used (130 KCL, 1 MgCl2, 0.045 CaCl2, 1 EGTA, 10 181 
HEPES, pH 7.2 with NaOH). KATP channel opening was stimulated with 200μM diazoxide 182 
prior to, and during application of 1μM [D-Arg7, D-Lys15, D-Lys23]-esculentin-2CHa(1-30) 183 
(Peptide 6). 184 
In vivo studies 185 
Adult male National Institutes of Health (NIH) Swiss mice (Harlan Ltd, UK) were housed 186 
individually in an air-conditioned room (22 ± 2 °C) with a 12-hour light: 12-hour dark cycle 187 
and maintained on a standard rodent diet (Trouw Nutrition, Cheshire, UK), with food and 188 
water available ad libitum. For acute in vivo studies, overnight fasted mice received an 189 
intraperitoneal injection of glucose alone (18 mmol/kg body weight) or in combination with 190 
esculentin-2CHa(1-30) or its analogues (75 nmol/kg body weight). This dose was chosen on 191 
the basis of results in previous studies examining glucoregulatory effects of amphibian skin 192 
peptides (Conlon et al. 2014). A small dose-response study was conducted using GLP-1 and 193 
the two most prominent glucose-lowering peptides (Peptides 6 and 9). Blood samples were 194 
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collected before injection and at times indicated in the Figures. All animal experiments were 195 
carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and 196 
‘Principles of laboratory animal care’ (NIH publication no. 86 – 23, revised 1985).  197 
Statistical analysis: Results were analysed using GraphPad PRISM Software (Version 6.0) 198 
and presented as mean ± S.E.M. Statistical analyses were performed using student’s t test 199 
(non-parametric) or one-way ANOVA followed by Bonferroni or Student-Newman-Keuls 200 
post hoc test wherever applicable. Area under the curve (AUC) analysis was performed using 201 
the trapezoidal rule with baseline correction. Membrane current-voltage relations were 202 
compared using 2-way repeated measures ANOVA with Bonferroni post hoc test. Results 203 
were considered significant if p < 0.05. 204 
Results 205 
Plasma stability of esculentin-2CHa(1-30) and analogues: 206 
Degradation of esculentin-2CHa(1-30) (Peptide 1) exposed to mouse plasma was 93% in 8 207 
hours (Table 2). Examination of degradation products by mass spectrometry suggests that the 208 
native peptide is cleaved by enzymes at the following sites: between Phe6 and Arg7, Arg7and 209 
Gly8, Lys11 and Phe12, Ser14 and Lys15, Leu17 and Gly18, Ala22 and Lys23 and Leu28 and Val29. 210 
Substitution with D-isomers of residues at position 7 (Peptide 2), position 15 (Peptide 3) and 211 
positions 7, 15 and 23 (Peptide 6) conferred resistance to degradation, with degradation 212 
ranging between 24-59% (Table 2). Substitution with D-lysine residues at position 23 213 
(Peptide 4) and at positions 15 and 23 (Peptide 5) reduced degradation to approximately 80% 214 
(Table 2). Peptide 6 was cleaved only at Lys11 and Phe12 and Leu28 and Val29 compared to 215 
esculentin-2Cha-GA30, thus substitution of residues with D-isomers at these positions 216 
protected the sites from enzymatic cleavage. Substitution of lysine residues at positions 15 217 
and 23 with L-ornithine (Peptide 7) and amidation of C-terminus (Peptide 8) did not confer 218 
resistance to degradation (Table 2). Addition of a C-8 fatty acid to lysine residue at position 219 
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15 (Peptide 9) or 23 (Peptide 10) conferred resistance to degradation (62 and 79% 220 
respectively, Table 2), with cleavage only at sites between Arg7and Gly8, Ala22 and Lys23 and 221 
Leu24 and Gly25 and Arg7and Gly8 and Leu24 and Gly25 respectively.  222 
Insulinotropic actions of esculentin-2CHa(1-30) and analogues:  223 
 Esculentin-2CHa(1-30) (Peptide 1) and analogues stimulated insulin release from BRIN-224 
BD11 cells significantly compared to respective control at glucose (5.6 mM) (p<0.05, 225 
p<0.01, p<0.001, Table 2). Substitution of residues at position 7 (Peptide 2), position 15 226 
(Peptide 3), position 23 (Peptide 4) and positions 7 and 15 (Peptide 5) with respective D-227 
isomers significantly increased insulin release from BRIN-BD11 cells (p<0.01, p<0.001, 228 
Table 2). Substitution with D-isomers at positions 7, 15 and 23 (Peptide 6) or with lysine 229 
residues at positions 15 and 23 with L-ornithine (Peptide 7) significantly increased insulin 230 
release from BRIN-BD11 cells compared with esculentin-2CHa(1-30) (Peptide 1) (p<0.001, 231 
Table 2). Amidation of C-terminus (Peptide 8) did not markedly affect insulin output from 232 
BRIN-BD11 cells compared to parent peptide (Table 2). Addition of a C-8 fatty acid to lysine 233 
residue at position 15 (Peptide 9) or 23 (Peptide 10) markedly increased insulin release from 234 
BRIN-BD11 cells (p<0.001, Table 2), with effects of Peptide 9 significantly greater than 235 
esculentin-2CHa(1-30) (p<0.01, Table 2). For native and all peptide analogues of esculentin-236 
2CHa(1-30), threshold concentration for stimulating insulin release ranged between 10-7 M 237 
and 3x10-6 M (Table 2). Insulinotropic actions of esculentin-2CHa(1-30) and its analogues 238 
were comparable to that of GLP-1 (Table 2).  239 
We confirmed that the insulinotropic actions of esculentin-2CHa(1-30) peptides were 240 
not due to cytotoxicity. Thus LDH release from BRIN-BD11 cells upon exposure to the 241 
peptides was similar to that observed in control incubations (Table 2). The only exception 242 
was Peptide 2 which appeared to induce significantly greater LDH release at 3x10-6 M 243 
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(p<0.001, Table 2). From the in vitro stability and insulin release studies, substitution of 244 
residues at positions 7, 15 and 23 (Peptide 6) with respective D-isomers and addition of a C-8 245 
fatty acid to lysine residue at position 23 (Peptide 9) appeared to  confer greater plasma 246 
stability  and  insulinotropic action  on esculentin-2CHa-GA30. As a result, the native form 247 
and these two superior analogues were carried forward for further studies. 248 
 As shown in Figure 1A,  esculentin-2CHa(1-30) and its analogues (Peptide 6, Peptide 249 
9) markedly increased glucose stimulated insulin secretion from isolated mouse islets at 10-6 250 
M concentration (p<0.05, p<0.01, Figure 1A). The effects induced were similar to those 251 
observed with stable forms of GLP-1 and CCK-8, namely exendin-4 and pggCCK-8 252 
respectively (p<0.01, Figure 1A). The insulinotropic actions were clearly glucose dependent 253 
in the case of esculentin-2CHa(1-30) peptides which did not affect insulin secretion at 3 mM 254 
glucose even at high concentrations (Figure 1A). Esculentin-2CHa(1-30) (Peptide 1) and its 255 
analogues (Peptide 6, Peptide 9) also stimulated insulin release from human clonal beta cell 256 
line, 1.1B4 (p<0.05, p<0.01, p<0.001, Figure 1B). Threshold concentration for stimulation of 257 
insulin secretion from 1.1B4 cells for esculentin-2CHa(1-30) was 10-8 M whereas threshold 258 
concentrations for modified peptides were 10-11 M (Figure 1B). The maximal effect appeared 259 
less than that induced by 10-6 M exendin-4 from 1.1B4 cells (Figure 1B). 260 
Mechanisms underlying insulinotropic actions of esculentin-2CHa(1-30) and analogues: 261 
Effects on intracellular cAMP levels: GLP-1 and forskolin markedly increased intracellular 262 
cAMP levels in BRIN-BD11 cells (p<0.001, Figure 2A). In contrast, esculentin-2CHa(1-30) 263 
and its analogues (Peptide 6 and 9) did not have any appreciable effect on cAMP levels 264 
(Figure 2A).  265 
Effects of drugs and ionic manipulation on insulinotropic activity :Forskolin, PMA,  GLP-266 
1, pggCCK, Peptide 1, Peptide 6 and Peptide 9 significantly increased insulin release from 267 
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BRIN -BD11 cells (p<0.05, p<0.01, p<0.001, Figure 2B). Overnight 18 h culture with PMA 268 
(10 nM ) to down-regulate PKC pathways (McClenaghan et al. 2006) reduced PMA, 269 
pggCCK8, Peptide 1, Peptide 6 and Peptide 9 stimulated insulin secretion compared to 270 
routine culture (p<0.05, p<0.01, Figure 2B), In contrast, the insulin-releasing action of 271 
forskolin or GLP-1 was not attenuated. Consistent with this, the AC inhibitor, NKY80 only 272 
significantly inhibited GLP-1 induced insulin secretion (p<0.05, Figure 2C), whereas the 273 
PLC inhibitor, U73122X significantly reduced pggCCK8, Peptide 1, Peptide 6 and Peptide 9 274 
induced insulin secretion (p<0.05, p<0.01, Figure 3A). The insulinotropic effect of GLP-1 275 
was not impaired by U73122X. Since esculentin-2CHa(1-30) peptides still evoked small 276 
increase of insulin release in presence of NKY80,  ionic pathways involved in insulin 277 
secretion were investigated. 278 
Verapamil and diazoxide did not affect basal insulin secretion while IBMX, KCl and 279 
tolbutamide markedly increased insulin release from BRIN-BD11 cells (p<0.05, p<0.01, 280 
Figure 3A). Verapamil reduced pggCCK8, Peptide 2 1 and Peptide 10 9 induced insulin 281 
secretion (p<0.05, Figure 3A) while diazoxide reduced the insulinotropic effects of GLP-1, 282 
pggCCK8, Peptide 1 and Peptide 9 compared to control (p<0.05, p<0.01, p<0.001, Figure 283 
3A).  Peptide 6 potentiated IBMX-induced insulin secretion (p<0.05, Figure 3A) while none 284 
of the peptides altered the stimulatory insulin secretory responses from cells depolarised with 285 
30 mM KCl (Figure 3A). GLP-1 and all peptides tested potentiated insulin secretion in the 286 
presence of tolbutamide (p<0.05, Figure 3A). Insulinotropic actions of GLP-1, pggCCK8 and 287 
all esculentin-2CHa(1-30) peptides were abolished in the absence of extracellular Ca2+ 288 
(Figure 3B).  289 
Effects on membrane potential and intracellular Ca2+:  Esculentin-2CHa(1-30) and its 290 
analogues (Peptide 6 and 9) increased membrane potential and depolarised BRIN-BD11 cells 291 
compared to 5.6 mM glucose control (p<0.05, p<0.01, p<0.001, Figure 4A,B). This was 292 
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accompanied by a significant increase in intracellular [Ca2+]i (p<0.05, p<0.001, Figure 4C,D). 293 
The magnitude of the effects was markedly less than that induced by a depolarising 294 
concentration of KCl but similar to GLP-1 (Figure 4).  295 
Actions at plasma membrane:   296 
FITC-esculentin-2CHa(1-30) was used to monitor interactions of the peptide at plasma 297 
membrane sites on BRIN-BD11 cells. Representative images showing cells incubated for 5-298 
90 min with the fluorescent tagged peptide are shown in Figure 5. Membrane binding by 299 
FITC-esculentin-2CHa(1-30) was evident on the membrane of discrete populations of cells 300 
after 5 min exposure, while fluorescence in cytoplasm of cells was also evident after 20mins 301 
incubation becoming progressive more intense over time up to 90mins, suggesting initial 302 
binding with the membrane followed by internalisation of the peptide. To probe further the 303 
membrane effects underlying changes in membrane potential and intracellular Ca2+, we 304 
examined the actions of [D-Arg7, D-Lys15, D-Lys23]-esculentin-2CHa(1-30) (Peptide 6) on 305 
BRIN-BD11 cells using patch clamp technique. This revealed that the depolarisation 306 
observed in Figure 4A was unlikely to be due to direct action of the peptide on KATP channels 307 
as when membrane current was recorded under selective recording conditions using the patch 308 
clamp technique, Peptide 6 (1 μM) had no effect on the amplitude of diazoxide activated 309 
KATP current measured at -80mV (Figure 6A) or mean current density at voltages between 20 310 
and -80mV (P>0.05, Figure 6B,C). 311 
Acute anti-hyperglycaemic activity of esculentin-2CHa(1-30) and analogues: 312 
As shown in Figure 7A, B, Peptide 6 and Peptide 9 significantly reduced the glycaemic 313 
excursion (p<0.05) when administered together with glucose to overnight fasted NIH Swiss 314 
TO mice. This was associated with elevated insulin concentrations, with Peptide 9 315 
significantly increasing integrated (AUC) plasma insulin values (p<0.01, Figure 7C,D). The 316 
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effects observed were broadly similar to those induced by an equal dose of GLP-1 (Figure 317 
7A-D).  Follow-up dose-response studies revealed that 75 nmol/kg body weight was the 318 
minimal effective anti-hyperglycaemic dose of GLP-1, Peptide 6 or Peptide 9 under the 319 
experimental conditions employed (p<0.05, Figure 7E). 320 
Discussion: 321 
Genetic influences and lifestyle factors promote the constantly increasing incidence of type 2 322 
diabetes, which is treated clinically by strategies that target pancreatic beta cell dysfunction 323 
and/or insulin resistance (Bailey, 2009, Irwin & Flatt, 2015). Recently peptide therapeutics 324 
for diabetes using stable mimetics of GLP-1 have received much attention due to their 325 
tolerability, potency and efficacy compared to small molecules drugs. Our recent 326 
observations reveal that esculentin-2CHa possesses potent insulinotropic actions and an 327 
analogue - [Lys28]-esculentin-2CHa, exerted beneficial effects on metabolism in high fat fed 328 
mice with insulin resistance and impaired glucose tolerance (Ojo et al. 2015c). We have 329 
observed that esculentin-2CHa(1-30), a truncated and more readily synthesised analogue of 330 
30 amino acids lacking the cyclic C-terminal domain, retains insulin-releasing activity. The 331 
present study investigates the stability, insulinotropic actions and mechanisms of insulin 332 
secretion of esculentin-2CHa(1-30) and designer analogues together with their possible 333 
development for treatment of type 2 diabetes.  334 
In vitro plasma degradation studies revealed that substitution with D-isomers of 335 
residues at position 7 (Peptide 2), position 15 (Peptide 3) and positions 7, 15, 23 (Peptide 6) 336 
and addition of a C-8 fatty acid to lysine residue at position 15 (Peptide 9) or position 23 337 
(Peptide 10) enhanced resistance to degradation by plasma proteolytic enzymes. Peptides 6, 9 338 
and 10 were partially degraded to 3 fragments after 8 h incubation with mouse plasma 339 
whereas esculentin-2CHa(1-30) was degraded to 5 fragments. Enhanced resistance to 340 
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degradation coupled with intact insulinotropic activity may be beneficial in vivo. Indeed, 341 
insulinotropic actions of modified analogues were well preserved in clonal BRIN-BD11 cells. 342 
These actions were not associated with cellular cytotoxicity as indicated by lack of leakage of 343 
the intracellular marker LDH.  344 
On the basis of enzymatic stability and insulin-releasing potency, three peptides were 345 
chosen for further evaluation, namely the analogue with triple D-isomer substitution (Peptide 346 
6), the acylated form of esculentin-2CHa(1-30) (Peptide 9) and for comparison the parent 347 
molecule, esculentin-2CHa(1-30) (Peptide 1). Studies using isolated mouse islets highlighted 348 
the glucose-dependent insulin-releasing properties of all three peptides, which exerted effects 349 
similar to those of stable analogues of GLP-1 and CCK-8 (exendin-4 and pggCCK-8, 350 
respectively). When tested using the novel electrofusion-derived human 1.1B4 cell line 351 
(McCluskey et al. 2011), the esculentin-2CHa(1-30) peptides stimulated concentration-352 
dependent insulin secretion with lower threshold stimulatory concentrations being observed 353 
for the modified analogues. These data indicate that these peptides should not induce 354 
hypoglycaemia are that they are likely to stimulate insulin secretion from human beta cells, 355 
with translational effects in vivo. 356 
Beta cell stimulus-secretion coupling is a complex process, with the involvement of 357 
many key players including KATP channels, ATP, PKA, PKC, cAMP, Ca2+, functional 358 
microtubule and microfilament system (McClenaghan, 2007, Fu et al. 2013). Beta cells detect 359 
changes in blood glucose levels and subsequent metabolism leads to increase in ATP levels 360 
that induces closure of plasma membrane KATP channels and depolarisation resulting in 361 
opening of voltage gated Ca2+ channels (VDCC) (McClenaghan, 2007, Drews et al. 2010, Fu 362 
et al. 2013). Ca2+ oscillations stimulate pulsatile insulin secretion with exocytosis of secretory 363 
granules which accounts for the first and early phase of insulin secretion. KATP channel 364 
independent mechanisms (Ca2+ dependent or independent) mediate the second phase of 365 
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insulin secretion. The KATP channel dependent pathway is considered to be the major trigger 366 
for glucose stimulated insulin secretion (GSIS), with amplification by pathways triggered by 367 
adenylate cyclase (cAMP, PKA) or phospholipase C (PKC) (Yaney et al. 2002, Doyle & 368 
Egan, 2007).  369 
 Inhibitors of  enzymes  (AC,  PLC) and ion  channels   (KATP, VDCC), fluorescent 370 
dyes to monitor membrane potential and intracellular Ca2+, measurement of second 371 
messengers such as cyclic AMP and electrophysiological techniques are useful to delineate 372 
mechanisms underlying the insulinotropic actions of novel peptides and drugs (Yaney et al. 373 
2002, Miguel et al. 2004, Drews et al. 2010, Hodson et al. 2014). We used these strategies to 374 
understand better the actions through which esculentin-2CHa(1-30) and its selected analogues 375 
elicited insulin secretion using BRIN-BD11 cells. Direct measurement of cyclic AMP 376 
showed that unlike GLP-1 (Dyachok et al. 2006, Ramos et al. 2008), esculentin-2CHa(1-30) 377 
peptides had little effect on cyclic AMP, resembling the actions of CCK-8. Consistent with 378 
this, downregulation of PKC pathway after overnight culture with PMA (Yaney et al. 2002) 379 
significantly reduced PMA, GLP-1, pggCCK8, Peptide 1, Peptide 6 and Peptide 9 induced 380 
insulin secretion. Similarly AC inhibition using NKY80 reduced GLP-1 induced insulin 381 
release but not the stimulatory effects of pggCCK8 or esculentin-2CHa(1-30) peptides.  382 
To establish involvement of ionic events, we studied the actions of diazoxide, high K+ 383 
solution, verapamil and depletion of Ca2+ on the effects of esculentin-2CHa(1-30) peptides. 384 
Each of these conditions inhibited the insulinotropic response. Consistent with these data, the 385 
insulin-secretory effects of the peptides on BRIN-BD11 cells were accompanied by 386 
depolarisation and increased intracellular Ca2+. Collectively, these findings suggested to us 387 
that the insulinotropic effects of esculentin-2CHa(1-30) peptides might result, at least in part, 388 
from the inhibition of KATP channels to cause depolarisation and voltage-dependent Ca2+ 389 
influx. In patch-clamp experiments, however, we found that esculentin-2CHa(1-30) peptides 390 
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had no direct effect on beta cell KATP channels. This raises the possibility of an action on 391 
other ion channels such as L-type Ca2+ channels a direct depolarising effect resulting from 392 
positively charged peptides entering the beta cell as suggested by imaging studies using 393 
fluorescently tagged FITC-esculentin-2CHa(1-30). Further studies will be required to 394 
evaluate such effects and the consequences of longer term exposure of beta cells to these 395 
peptides. 396 
Cell-penetrating peptides are receiving increasing interest as vehicles for intracellular 397 
delivery of therapeutic agents such as anti-cancer drugs (Kurrikoff et al . 2016). The relatively 398 
rapid and efficient internalization of FITC-esculentin-2CHa(1-30) by BRIN-BD11 cells, 399 
without loss of integrity of the plasma membrane, suggests a possible application for  400 
enzyme-resistant analogues of the peptide. In this regard, esculentin-2CHa(1-30) resembles 401 
the amphibian histone H2A-derived peptide buforin II (Elmore. 2012). Buforin II traverses 402 
the cell membrane in a cooperative manner without producing significant damage by a 403 
mechanism that involves formation of transient toroidal pore structures. Once internalized, 404 
buforin II accumulates in the nucleus and alters cellular function (Lee et al. 2008). Studies in 405 
vivo (unpublished data) have shown that treatment of high fat-fed mice with esculentin-406 
2CHa(1-30) and its analogues  ameliorates diabetes and has beneficial effects on expression 407 
of  pancreatic islet genes involved with insulin release suggesting that the internalized peptide 408 
may also be able to regulate transcription. 409 
  In conclusion, the present study has shown that analogues of esculentin-2CHa(1-30), 410 
namely [D-Arg7, D-Lys15, D-Lys23]-esculentin-2CHa(1-30) and Lys15-octanoate-esculentin-411 
2CHa(1-30) (Peptides 6 and 9 respectively demonstrate enhanced resistance to degradation 412 
by endopeptidases and strong insulinotropic actions on rat and human clonal beta cells as 413 
well as primary mouse islets. These peptide analogues also exerted anti-hyperglycaemic 414 
effects and promoted glucose-induced insulin release normal mice. Detailed studies 415 
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investigating the effects of chronic administration of these peptides in animal models of 416 
obesity-diabetes are needed to further explore the potential of esculentin-2CHa(1-30) 417 
analogues for therapy of diabetes in man. 418 
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Table 1 Amino acid sequences and molecular masses of esculentin-2CHa, esculentin-2CHa(1-30) and substituted analogues 
Peptide 
No. 
Name Primary Sequence Theoretical 
molecular mass 
(Da) 
Measured 
molecular mass 
(Da) 
 Esculentin-2CHa GFSSIFRGVAKFASKGLGKDLAKLGVDLVACKISKQC 3841.6      - 
1 Esculentin-2CHa-(1-30) GFSSIFRGVAKFASKGLGKDLAKLGVDLVA 3052.6 3053.7 
2 [D-Arg7]-Esculentin-2CHa-
(1-30) 
GFSSIFRGVAKFASKGLGKDLAKLGVDLVA 3052.6 3053.1 
3 [D-Lys15]-Esculentin-2CHa-
(1-30) 
GFSSIFRGVAKFASKGLGKDLAKLGVDLVA 3052.6 3052.0 
4 [D-Lys23]-Esculentin-2CHa-
(1-30) 
GFSSIFRGVAKFASKGLGKDLAKLGVDLVA 3052.6 3054.0 
5 [D-Lys15,D-Lys23]-
Esculentin-2CHa-(1-30) 
GFSSIFRGVAKFASKGLGKDLAKLGVDLVA 3052.6 3053.8 
6 [D-Arg7, D-Lys15,D-Lys23]-
Esculentin-2CHa-(1-30) 
GFSSIFRGVAKFASKGLGKDLAKLGVDLVA 3052.6 3053.9 
7 [L-Orn15, L-Orn23]-
Esculentin-2CHa-(1-30) 
GFSSIFRGVAKFASOrnGLGKDLAOrnLGVDLVA 3024.5 3026.3 
8 Esculentin-2CHa-(1-30)-NH2 GFSSIFRGVAKFASKGLGKDLAKLGVDLVA-NH2 3051.6 3051.0 
9 Lys15-octanoate -Esculentin-
2CHa-(1-30) 
GFSSIFRGVAKFASK(Oct)GLGKDLAKLGVDLVA 3178.6 3177.5 
10 Lys23-octanoate -Esculentin-
2CHa-(1-30) 
GFSSIFRGVAKFASKGLGKDLAK(Oct)LGVDLVA 3178.6 3176.6 
Table 2 Degradation of esculentin-2CHa(1-30) peptides in plasma and effects on insulin 
and LDH release from clonal BRIN BD11 cells compared with established 
secretagogues 
Secretagogue/Peptide % Degradation 
(8 h in mouse 
plasma) 
BRIN-BD11 cells 
Insulin release 
(ng/million 
cells/20 min) 
Threshold 
concentration 
LDH release 
(% of 
control) 
Glucose (5.6 mM) -- 0.75 ± 0.04 -- 102.8 ± 5.4 
Glucose (16.7 mM) -- 1.36 ± 0.10***  -- 106.9 ± 1.3  
Alanine (10 mM) -- 5.00 ± 0.50***  -- 106.1 ± 1.8 
GLP-1 (7-36) NH2 (10-
6 M) 
-- 1.96 ± 0.17*** -- 94.7 ± 5.3 
Peptide 1 (3 x 10-6 M) 93 1.32 ± 0.04*** 10-7 M 105.9 ± 5.7  
Peptide 2 (3 x 10-6 M) 59 1.57 ± 0.04***, ΔΔ 3 x 10-7 M 128.2 ± 5.4***
Peptide 3 (3 x 10-6 M) 46 1.06 ± 0.08
**, ΔΔ 3 x 10-6 M 122.6 ± 1.4 
Peptide 4 (3 x 10-6 M) 80 1.22 ± 0.03***, ΔΔ 3 x 10-7 M 107.6 ± 4.6 
Peptide 5 (3 x 10-6 M) 81 1.06 ± 0.04**, ΔΔ 10-6 M 90.1 ± 1.6 
Peptide 6 (3 x 10-6 M) 24 1.96 ± 0.08***, ΔΔ 10-6 M 114.6 ± 5.9 
Peptide 7 (3 x 10-6 M) 94 2.75 ± 0.09***, ΔΔΔ 3 x 10-7 M 100.1 ± 4.2 
Peptide 8 (3 x 10-6 M) 92 1.13 ± 0.09*,Δ 3 x 10-6 M 92.9 ± 8.8 
Peptide 9 (3 x 10-6 M) 62 2.47 ± 0.12***, ΔΔ 3 x 10-6 M 105.0 ± 6.8 
Peptide 10 (3 x 10-6 M) 79 1.65 ± 0.15*** 10-6 M 106.8 ± 4.3 
 
Values are mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001 compared to respective control 
at glucose (5.6 mM). Δp<0.05, ΔΔp<0.01, ΔΔΔp<0.001 compared to esculentin-2CHa(1-30) 
(Peptide 1). 
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